Visible Genetics targets disease diagnostics
This article was originally published in Clinica
Executive Summary
Visible Genetics is nearing completion of trials of its p53 GeneKit for breast cancer and expects to publish results within "several months". The Canadian company has developed three gene- specific test kits using stratified matrix testing methods to identify disease-associated mutations. The kits are designed to run on the company's DNA sequencer, the OpenGene system, which is based on ultra-thin electrophoretic gel cassette technology.